MEDNAX, Inc. (NYSE:MD) Receives $26.50 Consensus PT from Brokerages

Shares of MEDNAX, Inc. (NYSE:MDGet Rating) have been given an average rating of “Hold” by the eight research firms that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $26.50.

MD has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft lowered their target price on shares of MEDNAX from $24.00 to $16.00 in a report on Tuesday, May 10th. TheStreet cut shares of MEDNAX from a “b-” rating to a “c+” rating in a research note on Wednesday, April 13th. StockNews.com cut shares of MEDNAX from a “buy” rating to a “hold” rating in a research note on Monday, May 2nd. Finally, Mizuho decreased their price target on shares of MEDNAX from $28.00 to $23.00 in a research note on Monday, May 2nd.

A number of large investors have recently bought and sold shares of MD. Prospera Financial Services Inc purchased a new position in MEDNAX during the 1st quarter valued at about $49,000. Point72 Hong Kong Ltd acquired a new stake in shares of MEDNAX during the 4th quarter worth about $57,000. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in shares of MEDNAX by 120.2% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 3,107 shares of the company’s stock worth $85,000 after purchasing an additional 1,696 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of MEDNAX by 159.6% during the 3rd quarter. Captrust Financial Advisors now owns 5,579 shares of the company’s stock worth $159,000 after purchasing an additional 3,430 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of MEDNAX by 831.3% during the 1st quarter. Acadian Asset Management LLC now owns 7,311 shares of the company’s stock worth $171,000 after purchasing an additional 6,526 shares during the last quarter. Hedge funds and other institutional investors own 95.68% of the company’s stock.

Shares of MD opened at $20.27 on Tuesday. MEDNAX has a fifty-two week low of $17.17 and a fifty-two week high of $35.67. The firm’s 50 day moving average price is $19.81 and its 200 day moving average price is $23.05. The company has a market cap of $1.77 billion, a P/E ratio of 18.94, a PEG ratio of 1.17 and a beta of 2.05. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.92.

MEDNAX (NYSE:MDGet Rating) last announced its earnings results on Thursday, April 28th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.06. MEDNAX had a net margin of 4.73% and a return on equity of 15.64%. The firm had revenue of $482.20 million for the quarter, compared to the consensus estimate of $471.29 million. During the same period in the prior year, the firm earned $0.20 EPS. The firm’s revenue for the quarter was up 7.9% on a year-over-year basis. Research analysts forecast that MEDNAX will post 1.73 earnings per share for the current year.

About MEDNAX (Get Rating)

MEDNAX, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

See Also

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.